Alterity Therapeutics Limited approved changes to CEO and Managing Director Dr David Stamler’s remuneration package, effective October 15, 2026. The package lists a US$525,000 annual base salary, a short-term incentive of up to 100% of annualized base salary based on agreed goals and milestones, and six months’ notice or payment in lieu.
The company intends to seek shareholder approval at its upcoming annual general meeting for termination benefits. Subject to applicable limits, termination without cause provides for a lump sum equal to 100% of then-current annual base salary, plus medical coverage premiums for 12 months or until comparable coverage through a subsequent employer, whichever is earlier, subject to a full release. The terms also provide for equity vesting and other benefits in specified change-of-control circumstances.
Alterity Therapeutics Limited (ATHE) announced that David Stamler, M.D., its Chief Executive Officer, will participate in a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on October 22, 2026, at 2:30 p.m. ET. An archived webcast link will be available afterward on the company website under Investors, Events and Presentations.
Alterity says it is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA). The company says its lead asset, ATH434, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in participants with MSA, and it reported positive data from an open-label Phase 2 trial in participants with advanced MSA.
Alterity Therapeutics Limited (ATHE) announced that Chief Executive Officer David Stamler, M.D., will present at the Canaccord Genuity Drug and Device Conference on October 12, 2026, at 3:50 p.m. AEST and host roundtable discussions with investors.
The clinical-stage biotechnology company focuses on disease-modifying therapies for multiple system atrophy (MSA) and related Parkinsonian disorders. Alterity identifies ATH434 as its lead asset and says it demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in participants with MSA. The company also reports positive data from an open-label Phase 2 trial in participants with advanced MSA.
Alterity Therapeutics Limited (ATHE) reported additional analyses from its Phase 2 ATH434-201 trial in multiple system atrophy. In a post hoc mixed-model analysis of 61 participants, adjusting for baseline CSF NfL, ATH434 50 mg showed approximately 52% slowing of functional decline versus placebo at Week 52. The difference in change from baseline on the 11-item UMSARS Part I was −4.64 points versus placebo (p=0.032).
Baseline CSF NfL predicted functional decline: each 1,000 pg/mL increase was associated with approximately 0.9 additional points of worsening at Week 52 (p=0.033), supporting its use as a severity covariate in future MSA trials. The trial's primary endpoint of change in substantia nigra iron at Week 52 was not met; dentate nucleus iron signal increased relative to placebo by 0.016 ppm in the 50 mg group (p=0.021).
Alterity Therapeutics Limited (ATHE) said its next Annual General Meeting will be held at 11.00am AEDT on November 20, 2026. Written director nominations must be received at the company’s registered office no later than 5.00pm AEST on October 2, 2026.
Shareholders will receive further AGM details in a separate Notice of Meeting.